Ponsiano Ocama1, Emmanuel Seremba2, Betty Apica2, Kenneth Opio1. 1. Makerere University College of Health Sciences, Department of Medicine, Gastroenterology Division, Mulago Hospital, Kampala, Uganda. 2. Mulago National Hospital, Division of gastroenterology, Kampala, Uganda.
Abstract
BACKGROUND: Hepatitis B virus (HBV) and HIV are endemic in Uganda. Co-infection is common and leads to rapid progression of liver disease. Burden of co-infection is unknown yet most patients are on lamivudine-only ART where resistance is frequent. Most patients are initiated on antiretroviral therapy (ART) without knowing their HBV status. OBJECTIVES: To determine burden of co-infection and HBV viral suppression among patients on ART in Northern Uganda. METHODS: We recruited HIV infected adult patients on ART in a cross-sectional study. Age, sex, ART regimen and duration were recorded. Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBcAb) and liver panel were performed. For those HBsAg+, hepatitis B e antigen (HBeAg) and HBV DNA were performed. CD4 cell count was recorded. RESULTS: Three hundred patients were recruited. Twenty (6.7%) were co-infected, while 41% were anti-HBcAb+. Overall 188 (62.7%) were on lamivudine- only HBV active drug. Median ART duration 2 years (IQR 1-5), mean CD4+ cell count 317 cells/microlitre (SD 255-557). Of 20 HIV/HBV co-infected, 11/20 (55%) were on lamivudine-only ART, median duration 1.5 years. Nineteen (95%) had undetectable HBV DNA. Seventeen (85%) were HBeAg negative. Mean CD4+ cell count 327 cells/microlitre (SD 197-482). CONCLUSION: A large proportion of patients were on lamivudine- only HBV-active ART. Resistance may occur long term thus testing for HBV and correct ART is recommended.
BACKGROUND:Hepatitis B virus (HBV) and HIV are endemic in Uganda. Co-infection is common and leads to rapid progression of liver disease. Burden of co-infection is unknown yet most patients are on lamivudine-only ART where resistance is frequent. Most patients are initiated on antiretroviral therapy (ART) without knowing their HBV status. OBJECTIVES: To determine burden of co-infection and HBV viral suppression among patients on ART in Northern Uganda. METHODS: We recruited HIV infected adultpatients on ART in a cross-sectional study. Age, sex, ART regimen and duration were recorded. Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBcAb) and liver panel were performed. For those HBsAg+, hepatitis B e antigen (HBeAg) and HBV DNA were performed. CD4 cell count was recorded. RESULTS: Three hundred patients were recruited. Twenty (6.7%) were co-infected, while 41% were anti-HBcAb+. Overall 188 (62.7%) were on lamivudine- only HBV active drug. Median ART duration 2 years (IQR 1-5), mean CD4+ cell count 317 cells/microlitre (SD 255-557). Of 20 HIV/HBV co-infected, 11/20 (55%) were on lamivudine-only ART, median duration 1.5 years. Nineteen (95%) had undetectable HBV DNA. Seventeen (85%) were HBeAg negative. Mean CD4+ cell count 327 cells/microlitre (SD 197-482). CONCLUSION: A large proportion of patients were on lamivudine- only HBV-active ART. Resistance may occur long term thus testing for HBV and correct ART is recommended.
Authors: C William Wester; Soyeon Kim; Hermann Bussmann; Ava Avalos; Ndwapi Ndwapi; Trevor F Peter; Tendani Gaolathe; Andrew Mujugira; Lesego Busang; Chris Vanderwarker; Peter Cardiello; Onalethata Johnson; Ibou Thior; Patson Mazonde; Howard Moffat; Max Essex; Richard Marlink Journal: J Acquir Immune Defic Syndr Date: 2005-11-01 Impact factor: 3.731
Authors: Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: Dina Hooshyar; Debra L Hanson; Mitchell Wolfe; Richard M Selik; Susan E Buskin; A D McNaghten Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: David Coetzee; Katherine Hildebrand; Andrew Boulle; Gary Maartens; Francoise Louis; Veliswa Labatala; Hermann Reuter; Nonthutuzelo Ntwana; Eric Goemaere Journal: AIDS Date: 2004-04-09 Impact factor: 4.177
Authors: Emmanuel Ochola; Ponsiano Ocama; Christopher G Orach; Ziadah K Nankinga; Joan N Kalyango; Willi McFarland; Charles Karamagi Journal: BMC Public Health Date: 2013-08-07 Impact factor: 3.295
Authors: E Seremba; J P Van Geertruyden; R Ssenyonga; C K Opio; J M Kaducu; J B Sempa; R Colebunders; P Ocama Journal: Vaccine Date: 2017-04-20 Impact factor: 3.641
Authors: Huw Price; David Dunn; Tamale Zachary; Tobias Vudriko; Michael Chirara; Cissy Kityo; Paula Munderi; Moira Spyer; James Hakim; Charles Gilks; Pontiano Kaleebu; Deenan Pillay; Richard Gilson Journal: AIDS Date: 2017-05-15 Impact factor: 4.177
Authors: F V Segala; G Micheli; C Seguiti; A Pierantozzi; R Lukwiya; B Odong; F Aloi; E Ochola; R Cauda; K De Gaetano Donati; A Cingolani Journal: Mediterr J Hematol Infect Dis Date: 2021-09-01 Impact factor: 2.576